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Abstract: Pseudophakic cystoid macular edema (PCME) is the most common complication 
of cataract surgery, leading in some cases to a decrease in vision. Although the pathogenesis of 
PCME is not completely understood, the contribution of postsurgical inflammation is generally 
accepted. Consequently, anti-inflammatory medicines, including steroids and nonsteroidal anti-
inflammatory drugs, have been postulated as having a role in both the prophylaxis and treatment 
of PCME. However, the lack of a uniformly accepted PCME definition, conflicting data on some 
risk factors, and the scarcity of studies comparing the role of nonsteroidal anti-inflammatory 
drugs to steroids in PCME prevention make the problem of PCME one of the puzzles of 
ophthalmology. This paper presents an updated review on the pathogenesis, risk factors, and 
use of anti-inflammatory drugs in PCME that reflect current research and practice.
Keywords: Pseudophakic cystoid macular edema, cataract surgery, cataract surgery complica-
tions, retina, post-operative complications
Introduction
Pseudophakic cystoid macular edema (PCME) is the most common complication of 
cataract surgery. Because of the heterogeneity of definitions and diagnostic criteria, 
its incidence has been reported to be between 1% and 30% (Table 1), with, however, 
an incidence of 1%–2% of clinically significant PCME in patients with no risk factors. 
Although in most cases, PCME is a self-limiting disorder; in rare cases, it can lead to 
long-term visual deterioration that is difficult to treat. Thus, it is important to discuss 
recent studies on PCME prevention and treatment measures, as well as the recom-
mendations of major ophthalmic societies.
Definition
Different methods have been used to diagnose PCME. It has been determined from 
angiographic findings by fluorescein angiography, from clinical findings by fundos-
copy, by deterioration in visual acuity, and from optical coherence tomography (OCT) 
findings of central subfield macular thickening. The incidence rates of PCME vary sub-
stantially according to the method of diagnosis (Table 1).1–11 Moreover, its incidence has 
decreased with less invasive and less traumatic cataract surgery techniques (Table 1). 
Thus, it is difficult to compare the incidence of PCME between studies that are based 
on different surgery techniques and different diagnostic techniques (Table 1).
Pathogenesis
Although PCME was described many years ago, its pathophysiology remains uncer-
tain and a multitude of mechanisms have been suggested. Various factors have been 
implicated in its development, including, but not limited to, inflammation, vascular 
instability, vitreomacular tractions, and light toxicity.12–14 Most researchers agree that 
Correspondence: Andrzej Grzybowski
Department of Ophthalmology, Poznań 
City Hospital, Szwajcarska 3, Poznań 
61-285, Poland
email ae.grzybowski@gmail.com 
Journal name: Clinical Interventions in Aging
Article Designation: Review
Year: 2016
Volume: 11
Running head verso: Grzybowski et al
Running head recto: Pseudophakic cystoid macular edema: update 2016
DOI: http://dx.doi.org/10.2147/CIA.S111761
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
14
4.
12
.1
33
 o
n 
10
-O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1222
Grzybowski et al
postoperative inflammation seems to be a major cause of 
PCME. It is postulated that surgical manipulation within the 
anterior chamber may lead to the release of arachidonic acid 
from uveal tissue, with the production of either leukotrienes 
via the lipoxygenase pathway or prostaglandins (PGs) via 
the cyclooxygenase (COX) pathway.15 Subsequently, inflam-
matory mediators diffuse posteriorly into the vitreous and 
disrupt the blood–retinal barrier. This disruption results in 
increased permeability of the perifoveal capillaries and fluid 
accumulation within the retina.16 It is not clear why the fluid 
leaking from the perifoveal capillaries accumulates within the 
macula, despite the massive production and distribution of 
inflammatory cytokines throughout the retina. The reduced 
fluid reabsorption within the macula may be explained, at 
least in part, by the absence of blood vessels within the avas-
cular zone combined with the high metabolic activity of the 
fovea.17 Patients with marked postoperative inflammation 
tend to develop PCME more frequently than others do.14 
This observation implies that the degree of inflammation 
determines the severity of PCME, which can range from 
very mild to clinically significant forms. As postoperative 
inflammation is inseparably linked to each cataract surgery 
procedure, noncomplicated cases also induce an increase in 
subclinical central macular thickness (CMT). In a study by 
Perente et al,18 the CMT measured by using OCT increased 
significantly between 1 and 6 months postoperatively. The 
typical PCME OCT scans for different times after cataract 
surgery are shown in Figures 1–3. In the study conducted by 
Von Jagow et al,19 a moderate increase in macular thickness 
between the first and sixth week after surgery was observed, 
but there was no significant correlation between CMT and the 
best-corrected visual acuity (BCVA). Sahin et al20 reported 
that a moderate CMT increase in the first 3 postoperative 
months did not cause vision impairment in patients without 
PCME and that macular thickness gradually decreased to 
baseline values by the end of the 3-month period. Akcay 
et al21 observed higher macular thickness in patients after 
complicated cataract surgery than in those whose procedure 
had been uneventful.
Increased risk of PCME
Many local, systemic, and surgery-related conditions were 
shown to increase the risk of PCME (Table 2), among which 
diabetes was the most common.11,16,22–25 Recently, some 
of these risk factors, including diabetes, capsule rapture, 
previous diagnosis of epiretinal membrane, uveitis, retinal 
vein occlusion, and retinal detachment repair, were con-
firmed in a retrospective database study based on 81,984 
surgeries.26 The same study showed that high myopia, 
age-related macular degeneration, or the use of a PG 
analog did not increase the risk of PCME and that the risk 
increased proportionally with increasing severity of diabetic 
retinopathy. Some of the methodology and findings of the 
study were, however, criticized.27
Singh et al28 published the results of a multicenter, ran-
domized, double-masked, placebo-controlled study in 263 
diabetic patients with nonproliferative diabetic retinopathy 
undergoing cataract surgery. The patients were random-
ized to receive nepafenac 0.1% or vehicle three times daily 
beginning on day 1 before the surgery through postoperative 
day 90. All patients also used prednisolone acetate 1.0% 
four times daily for 2 weeks after surgery. The OCT scan 
performed on days 30 and 90 revealed macular edema in a 
significantly greater proportion of patients from the sham 
Table 1 Incidence of PCMe in different cataract extraction techniques in uncomplicated cataract operations
Cataract extraction technique Incidence of clinically  
significant PCME
Incidence of PCME  
defined by FA
Incidence of PCME 
defined by OCT
Intracapsular cataract extraction 8%1 36%–60%5 Not available
extracapsular cataract extraction 0.8%–20%2 16%–32.2%6,7 Not available
Phacoemulsification 0.1%–2.35%3 20%–54.7%8,9 3%–41%10,11
Femtosecond-assisted cataract surgery 1.18%4 1.18%4
Abbreviations: PCME, pseudophakic cystoid macular edema; FA, fluorescein angiography; OCT, optical coherent tomography.
Figure 1 OCT 5 weeks after cataract surgery.
Note: visual acuity =0.4.
Abbreviation: OCT, optical coherent tomography.
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treatment group than from the nepafenac group. The use 
of nepafenac also resulted in better visual acuity at all 
time points. However, the control eyes were treated with 
prednisolone acetate 1% for only 2 weeks after surgery, 
whereas the eyes from the nepafenac group received therapy 
lasting for more than 90 days, including day 1 preceding 
the surgery, which could have affected the study results. 
Henderson et al23 presented a retrospective analysis follow-
ing resident-performed cataract surgery accompanied by 
preventive regimens based on either topical steroid alone, 
topical nonsteroidal anti-inflammatory drugs (NSAIDs) 
alone (diclofenac 0.1% or ketorolac tromethamine 0.5% for 
times daily), a combination of both, or neither. They found 
the rate of PCME development in patients with diabetes, 
posterior capsule tear, or vitreous loss who received topical 
NSAIDs for 3 months after cataract surgery to be similar to 
that in low-risk patients. This result supports the preventive 
use of NSAIDs for the first 3 postoperative months following 
complicated cataract surgery, as well as for diabetic patients. 
Almeida et al,29 in an open-labeled nonmasked randomized 
study, compared ketorolac with placebo in high-risk patients 
with uveitis, diabetes, or macular disease after cataract 
surgery, observing a significantly decreased macular volume 
in patients receiving ketorolac. Therefore, they concluded 
that in high-risk patients, preventive use of topical NSAIDs 
is an effective and safe intervention to minimize postopera-
tive macular edema. Meyer and Schönfeld30 presented a case 
report of PCME following complicated cataract surgery 
treated successfully with a 0.7-mg dexamethasone intravitreal 
implant (Ozurdex) after three previous ineffective intravitreal 
injections of 0.4 mg of dexamethasone.
PCME treatment
Modern cataract surgery is an efficient procedure and is 
generally associated with good visual results. However, 
despite recent surgical improvements, after PCME develops, 
postoperative vision can be suboptimal. To ensure a favorable 
outcome, one ought to know when and how to effectively 
treat this complication.
Treatment options correspond to many postulated mecha-
nisms for the formation of PCME. Corticosteroids and 
topical NSAIDs, either as monotherapy or combined therapy, 
are a commonly used first-line treatment approach.31 When 
this approach is ineffective, intravitreal application of 
corticosteroids and anti-vascular endothelial growth factor 
agents may be an option. In eyes with chronic PCME and 
vitreomacular traction, pars plana vitrectomy can be consid-
ered. This topic is discussed extensively elsewhere.31
The role of corticosteroids in the treatment of PCME 
involves the inhibition of leukotriene and PG synthesis.32 
Corticosteroids decrease PG production by inhibiting phos-
pholipase A2 in the arachidonic acid cascade. In addition to 
their anti-inflammatory properties, corticosteroids also inhibit 
macrophage and neutrophil migration and decrease capillary 
permeability and vasodilation.33 They exert a broader anti-
inflammatory effect than do NSAIDs and have a much longer 
track record of use, which makes many ophthalmologists 
reluctant to substitute NSAIDs for corticosteroids as part of 
inflammation management after cataract surgery. Of note is 
that differences in concentration, lipophilicity, and innate 
glucocorticosteroid activity among individual corticos-
teroid formulations may change their anti-inflammatory 
effect within the eye. It is essential to accommodate these 
Figure 2 OCT 6 weeks after cataract surgery.
Abbreviation: OCT, optical coherent tomography.
Figure 3 OCT 3 months after cataract surgery.
Note: visual acuity =1.0.
Abbreviation: OCT, optical coherent tomography.
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differences in order to properly interpret the therapeutic effect 
of comparative or combination treatment with NSAIDs.
NSAIDs work by inhibiting the COX enzymes. They 
are active in the inflammatory process, catalyzing the 
biosynthesis of eicosanoids from arachidonic acid to pro-
duce PGs and thromboxanes.33 PGs within the eye produce 
vasodilatation and disruption of the blood–ocular barrier.34 
The main isoforms of COX are COX-1 and COX-2. COX-1 
is a constitutive enzyme involved in the regulation of physi-
ologic processes. COX-2 is an inducible enzyme, expressed 
primarily in inflammatory responses and in relation to pain 
or fever.34 The development of COX-2-selective NSAIDs 
was proposed to relieve pain and inflammation without the 
adverse effects of the COX-1 blockade. Several ophthalmic 
NSAID formulations are available on the market, each with 
individual properties. The advantages of NSAIDs over 
corticosteroids include good intraocular pressure control and 
stability, reduced risk of secondary infections, and additional 
analgesic effect.8,35,36 However, typically NSAIDs (except 
for celecoxib and diclofenac), in contrast to corticoster-
oids, do not inhibit lipoxygenase, and thus do not prevent 
the production of leukotrienes. Moreover, NSAIDs were 
shown to have anti-inflammatory and antiangiogenic effects 
independent of their inhibition of COX. Good evidence 
suggests that topical NSAIDs reduce postoperative inflam-
mation after cataract surgery.34 It was argued that the greater 
therapeutic effect of NSAIDs plus corticosteroids is due to 
the additive rather than the synergistic effect of two anti-
inflammatory drugs.34
Shelsta and Jampol37 suggested a stepwise algorithm 
for PCME treatment. They recommended starting with the 
initial combination of a topical NSAID (less expensive 
variety) and a topical corticosteroid, and then considering 
a more expensive topical NSAID when there is no vision 
improvement after 4–6 weeks. For refractory cases, they pro-
posed intravitreal corticosteroid injection. Benhamou et al38 
administered repeated intravitreal triamcinolone injections to 
patients with refractory PCME who showed decreased macu-
lar thickness in OCT studies. Nevertheless, all patients had 
a recurrence of macular edema within 2–4 months. Bellocq 
et al39 assessed the effectiveness of intravitreal dexametha-
sone implants (Ozurdex) for treating PCME, mainly after 
cataract surgery that was refractory to first-line treatment 
(the EPISODIC study). They found that more than half of the 
patients who were followed-up for at least 1 year presented 
neither a functional nor an anatomical recurrence. In patients 
who received two injections, the effectiveness and safety of 
the two implants were similar. The same authors also studied 
the effectiveness of the dexamethasone implant in PCME 
in a larger sample of patients with longer follow-up (the 
EPISODIC-2 study).40 The results not only confirmed those 
obtained in the pilot study but also provided new information. 
Only the absence of PCME risk factors at diagnosis proved 
to be a good predictor of functional effectiveness, while the 
patient’s age, type of surgery, initial visual acuity, naive 
status, and time of first injection did not constitute predictive 
factors for good response to treatment (defined as a gain of 
ten letters in BCVA during follow-up). Falavarjani et al41 
Table 2 Factors associated with an increased risk of PCMe
Systemic conditions Ocular conditions Surgery associated
Age (elderly, children)
Arteriosclerotic vascular disease, 
including hypertension and diabetes
Ocular inflammatory diseases
Retinal vascular diseases
Diabetic retinopathy and maculopathy
Choroidal neovascularization
Drug reactions, including topical epinephrine and epinephrine-like 
drugs, prostaglandin analogs, and high oral doses of nicotinic acid
Retinal dystrophies, including retinitis pigmentosa and Goldmann–
Favre syndrome
Tractional maculopathies, including idiopathic epiretinal membranes
Retinal detachment and retinal detachment surgery
Intraocular tumors
Optic nerve head abnormalities, including optic pit, optic nerve 
coloboma (typical and atypical), and morning glory disc anomaly
Penetrating keratoplasty
vitreous surgery
Laser surgery
Cryotherapy and segmental buckling of retinal tears without 
detachments
Additional trauma during 
surgery, especially to the iris
Posterior capsule rupture
vitreous loss, vitreous traction
High phaco energy
Long duration of the surgery
Abbreviation: PCMe, pseudophakic cystoid macular edema.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
14
4.
12
.1
33
 o
n 
10
-O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1225
Pseudophakic cystoid macular edema: update 2016
reviewed the use of intravitreal bevacizumab injection for 
the treatment of PCME. They did not find any high-quality 
evidence to recommend anti-vascular endothelial growth 
factor agents as a routine treatment for PCME. However, 
they concluded that bevacizumab injection can be considered 
in patients with refractory PCME that is unresponsive to 
intravitreal steroids. Wu et al42 reported short-term structural 
and functional outcomes following intravitreal injection of 
infliximab in eyes with refractory PCME treated previously 
with topical nepafenac 0.1%, topical prednisolone acetate 
1%, intravitreal triamcinolone (4 mg), and intravitreal 
bevacizumab (1.25 mg). Most patients experienced BCVA 
improvement by at least $3 lines at the 6-month follow-up. 
BCVA deterioration was not reported in any case. Khurana 
et al43 have also shown a benefit of dexamethasone implants 
for patients with diabetes who develop PCME after cataract 
surgery. Harbour et al44 demonstrated a beneficial effect 
of pars plana vitrectomy in eyes with chronic PCME and 
vitreomacular traction.
PCME prevention
Prevention of PCME includes the least invasive surgery pos-
sible with no complications, short surgery time, and in some 
cases, the use of anti-inflammatory pharmacological agents. 
The latter subject is presently a topic of hot debate between 
those who advocate the standard use of NSAIDs in all cataract 
operations and those who advocate their use only in high-risk 
cases. Since many PCME cases are mild and resolve spon-
taneously, accurately estimating the therapeutic benefits of 
the available anti-inflammatory drugs is challenging. It is not 
easy to precisely determine the extent to which the preventive 
use of anti-inflammatory therapies may improve long-term 
visual outcomes. Therefore, the answer to the question about 
whether such treatment prevents chronic PCME or reduces 
its severity is not as obvious as it may initially seem. The 
differences in methodology between the studies assessing 
the efficacy of PCME prevention and treatment make this 
analysis even more difficult. Because macular edema can 
be diagnosed from clinical examination, fluorescein angiog-
raphy, or OCT (Table 1),45–47 the diagnostic management 
of PCME directly affects the inclusion criteria for related 
clinical studies. As a result, some researchers investigate 
only clinically significant PCME, whereas others may study 
asymptomatic subclinical PCME as well. In addition, in some 
studies, patients were administered anti-inflammatory drugs 
preoperatively, which may have affected the evaluation of the 
efficacy of drugs used postoperatively. Furthermore, the com-
pared substances differed in their ocular tissue penetration 
(eg, topical NSAIDs vs 0.1% fluorometholone, which has 
a limited intraocular penetration); hence, such studies may 
only approximate the efficacy of NSAIDs compared with 
placebo.47,48 Estimating the therapeutic benefits of NSAIDs 
is also not straightforward because most studies involve the 
concomitant use of corticosteroids. Moreover, the results 
of the studies can differ according to the proinflammatory 
potential of a given patient at baseline (preexisting uveitis or 
diabetes). One should also remember that since the incidence 
of PCME is very low, trials must have a proper sample size 
to find any statistically significant and clinically relevant 
differences. If the particular study cannot find a statistically 
significant difference, this does not always mean that the 
treatment is not effective.
Many studies assessing the effectiveness of NSAIDs 
in the perioperative period for the prevention of PCME in 
extracapsular and intracapsular cataract surgeries are of 
historical relevance today, and thus will not be presented 
here. We discuss the most recent and relevant studies in the 
following paragraphs.
Almeida et al47 in a prospective, placebo-controlled, 
parallel-assignment, double-masked, randomized clinical 
trial compared the effect of topical nepafenac 0.1%, 
ketorolac 0.5%, and placebo on PCME in patients after 
modern-day phacoemulsification surgery with posterior 
chamber intraocular lens implantation. The patients used 
one of the aforementioned substances four times daily 
for 4 weeks, starting 1 day before the planned surgery. 
In addition, all patients were administered prednisolone 
acetate 1.0% eyedrops four times daily over the first 
week postoperatively. The dose was then tapered by one 
drop every week. The OCT performed at baseline and at 
4 weeks postoperatively did not show a significant retinal 
thickening in subjects treated with NSAIDs. While a mild 
CMT increase in placebo eyes was noted, at 4 weeks there 
was no significant difference in the ultimate visual acuity 
between the groups. The study concluded that in low-risk 
patients, the use of topical nepafenac or ketorolac does 
not seem to offer benefit over placebo in preventing OCT 
changes indicative of macular edema after surgery. Other 
authors found no significant differences between diclofenac 
0.1% and ketorolac 0.45% groups in macular thickness 
1 month after uneventful surgery.49 However, at the second 
postoperative month, the ketorolac group had significantly 
lower central subfield thickness than the diclofenac group. 
Wang et al50 compared the efficacy of bromfenac 0.1% 
administered twice daily for 4 weeks, bromfenac 0.1% 
administered twice daily for 8 weeks, fluorometholone 
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0.1% administered three times daily for 4 weeks, and 
dexamethasone 0.1% administered three times daily for 
4 weeks. All patients also received 15 mg of prednisone in 
one daily dose for 7 days postoperatively. No topical anti-
inflammatory drugs were used preoperatively. At 2 months, 
the mean OCT-based retinal thickness was significantly 
lower in both bromfenac groups. However, there were no 
significant differences in visual acuity between the groups. 
Wittpenn et al,51 in a randomized and masked comparison, 
reported a low incidence of OCT-confirmed PCME in 
low-risk patients treated with prednisolone acetate 1.0% 
in monotherapy and no difference in visual acuity if com-
bined with ketorolac 0.4% (corticosteroid vs corticosteroid 
plus NSAID). Shorstein et al52 found, in turn, that adding a 
prophylactic NSAID to postoperative topical prednisolone 
acetate was associated with a reduced risk of acute macular 
edema with visual acuity of 20/40 or worse.
A randomized double-blind study showed that applica-
tion of an anti-inflammatory drug for 3 days before surgery 
reduces PCME and improves vision in the short term, but 
there is no evidence that this practice affects long-term 
outcomes.53 Donnenfeld et al,53 in a randomized double-
masked study, assessed the effect of different preoperative 
dosing regiments of ketorolac 0.4% on postoperative PCME 
and visual acuity. They randomized treated eyes to one of 
four groups: the eyes in the first group received ketorolac for 
3 days before cataract surgery, in the second group for 1 day, 
and in the third group for 1 hour before cataract surgery, while 
the fourth group received placebo. Postoperatively, all three 
active treatment arms were administered ketorolac four 
times daily for 3 weeks, while the controls received placebo. 
In addition, all eyes were postoperatively administered topical 
prednisolone acetate 1.0% four times daily for 2 weeks fol-
lowed by twice daily for 1 week. At 2 weeks, the eyes pre-
treated with ketorolac for 1 or 3 days had significantly better 
visual acuity than did the placebo eyes, but this effect was 
not sustained for up to 3 months. The results suggest that the 
use of NSAIDs for up to 3 days before surgery accelerates 
visual recovery in the immediate postoperative period, but it 
does not affect the ultimate visual outcomes at 3 months after 
surgery. In contrast, Tzelikis et al,54 in a prospective, placebo-
controlled, randomized study, reported the inefficacy of 
ketorolac 0.4% and nepafenac 0.1% administered for 2 days 
before surgery and continued for 4 weeks postoperatively 
in OCT-assessed PCME prevention in eyes after unevent-
ful cataract surgery, compared with placebo. They did not, 
however, compare preoperative prophylactic treatment with 
postoperative treatment alone.
PREMED study
The European Society of Cataract and Refractive Surgeons 
funded a 2-year, multicenter, double-blind randomized 
study, the Prevention of Macular Edema After Cataract 
Surgery (PREMED), which started recruiting patients in 
2013 and is expected to provide evidence-based guidelines 
for PCME prevention and treatment after cataract surgery 
in patients without and with diabetes.55 In the nondiabetic 
population, the patients receive bromfenac 0.09% eye drops 
twice per day starting 2 days preoperatively and for 2 weeks 
postoperatively + dexamethasone 0.1% eye drops four times 
per day starting 2 days before surgery and continuing four 
times per day during the first postoperative week and one 
drop less per day every following week; or bromfenac 0.09% 
eye drops twice per day starting 2 days before surgery and for 
2 weeks postoperatively; or dexamethasone 0.1% eyedrops 
for times per day starting 2 days before surgery and continu-
ing for times per day during the first postoperative week 
and one drop less per day every following week. In patients 
with diabetes, there are four groups: 1) NSAID (bromfenac 
0.09%) + corticosteroid (dexamethasone 0.1%) eyedrops; 
2) NSAID + corticosteroid eyedrops + subconjunctival 
injection of 40 mg triamcinolone acetonide perioperatively; 
3) NSAID + corticosteroid eyedrops + intravitreal injection 
of 1.25 mg bevacizumab perioperatively; and 4) NSAID + 
corticosteroid eyedrops + subconjunctival injection of 40 mg 
triamcinolone acetonide +1.25 mg bevacizumab intravitreal 
perioperatively.55
Recommendations
No official US Food and Drug Administration (FDA)-
approved strategy for PCME prevention after cataract 
surgery is available, but an extensive meta-analysis of the 
literature in 1998 concluded that treatment with NSAIDs 
is beneficial.56 The next major review published in 2010 
reported similar findings, emphasizing the lack of evidence 
of a long-term benefit in preventing PCME-induced vision 
loss.34 A Cochrane full systematic review assessing the effects 
of NSAIDs in the treatment of PCME after cataract surgery 
was reported in 2012.57 This review found two randomized 
controlled trials that showed that a topical NSAID (0.5% 
ketorolac tromethamine ophthalmic solution) has a positive 
effect on chronic PCME and two randomized controlled trials 
that revealed no significant difference between comparative 
groups. The authors concluded that the effects of NSAIDs 
in acute and chronic PCME remain unclear and need further 
investigation. A recent systemic review and subsequent meta-
analysis from 2014 found NSAIDs to be more effective than 
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topical corticosteroids in preventing PCME.58 However, this 
meta-analysis may be limited by the tendency of researchers 
and journals to publish studies with positive findings rather 
than those showing little or no effect.48
In 2015, the American Academy of Ophthalmology 
(AAO) published a literature review on the clinical efficacy 
and safety of using topical NSAIDs to prevent PCME-
induced vision loss after cataract surgery.48 The researchers 
retrieved 149 unique citations and selected 27 articles of 
possible clinical relevance for a full-text review. Of these 
27 articles, 12 were deemed pertinent enough to be analyzed 
in full. They also identified two additional articles from the 
reference list of the selected articles and one conference 
presentation. The AAO Ophthalmic Technology Assessment 
Committee Retina/Vitreous Panel rated each selected citation 
according to the level of scientific evidence. The findings of 
the analysis were as follows: 1) NSAID therapy is effective 
in reducing PCME detected by angiography or OCT and 
may accelerate visual recovery after surgery when compared 
directly with placebo or topical corticosteroid formulations 
of limited intraocular penetration; 2) the use of NSAIDs does 
not alter the long-term ($3 months) visual outcomes; 3) there 
is no evidence that the benefits of NSAID therapy could not 
be obtained with equivalent dosing of a corticosteroid; and 
4) the literature does not support a seemingly synergistic 
effect of using both a NSAID and a corticosteroid, which 
seems unlikely given the overlapping mechanisms of action 
of both drug groups.59 This analysis suggests that, although 
dosing of NSAIDs before surgery may accelerate visual 
recovery within the first several weeks after cataract surgery, 
there is no level I evidence to support the long-term (3 months 
or more) use of NSAIDs in preventing vision loss secondary 
to PCME after cataract surgery.
Another systematic review and meta-analysis evaluating 
the optimum medical strategy to prevent PCME after uncom-
plicated cataract surgery was also published in 2015.60 The 
authors performed an extensive literature search, reviewed 
161 full-text articles, and included 30 individual random-
ized clinical trials. They excluded studies investigating 
intracapsular or extracapsular cataract extraction. In non-
diabetic patients, topical NSAIDs, compared with topical 
corticosteroids, were found to significantly reduce the odds of 
developing PCME. The study also demonstrated that a combi-
nation of topical NSAIDs and corticosteroids, compared with 
topical corticosteroids alone, significantly reduced the odds 
of developing PCME, whereas the combination treatment 
did not show any benefit over topical NSAIDs alone in an 
indirect treatment comparison. Therefore, the authors drew 
the conclusion that topical NSAIDs should always be part 
of the preventive treatment after cataract surgery in nondia-
betic patients. In diabetic patients, the odds of developing 
PCME were significantly lower after topical combination 
treatment with NSAIDs and corticosteroids, compared with 
a single-drug treatment with topical corticosteroids. It was, 
however, pointed out that the review included studies of all 
PCME, regardless of whether or not it was associated with 
decreased vision, and that it provided no information to 
support the conclusion that NSAIDs are more effective than 
corticosteroids at reducing PCME.61
Guidelines of the Royal College of Ophthalmologists 
recommend the use of topical NSAIDs before and after surgery 
in patients at increased risk of PCME, eg, with diabetes, 
previous PCME, previous retinal vein occlusion, epiretinal 
membrane, and PG use.62 The Canadian Ophthalmological 
Society notes that prophylaxis with topical NSAIDs reduces 
the rate of early angiographic PCME, but this difference is not 
significant in long-term follow-up periods, and it is unknown 
whether prophylactic treatment with NSAIDs translates 
to a decrease in the development of late-onset PCME 
after the NSAIDs have been discontinued.63 Nevertheless, 
Canadian Ophthalmological Society concludes that steroids, 
NSAIDs, or both are recommended in the perioperative 
period (“Consensus”).63 The first-line therapy mandated 
by the French Society of Ophthalmology for symptom-
atic PCME is acetazolamide along with topical NSAIDs 
and corticosteroids.64
Critical summary
First, whereas most topical NSAID formulations are FDA-
approved for preventing inflammation after cataract surgery, 
the FDA-approved time limit for such treatment is 14 days. 
Most topical NSAIDs are not approved for PCME prevention 
or treatment.47 Second, many studies focused on the reduc-
tion of angiography-based PCME as a primary end point, 
which is problematic because angiographic PCME does not 
show a strong correlation with visual acuity.2,45,65 In addi-
tion, there is no commonly accepted method of reporting 
OCT-based PCME, which hinders the assessment of treat-
ment outcomes.28,49,50 Third, some studies may have favored 
NSAID treatment by preferential pretreatment with NSAIDs 
in one study arm.28,45,47,51 In other studies, no adjustment was 
made for dosing disparities between groups treated with a 
corticosteroid alone and with the combination of a NSAID 
and a corticosteroid.51
An evaluation of the currently available published data 
does not define the optimum prevention of PCME, which still 
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remains unclear and requires further investigation. Placebo-
controlled, double-masked, randomized clinical trials are 
largely lacking. Nevertheless, all studies discussed herein 
provide clinical evidence that the use of an anti-inflammatory 
drug before surgery reduces PCME and improves vision in 
the short term. Current evidence does not suggest, however, 
that this management strategy affects long-term outcomes.48 
Such prevention may prove particularly beneficial in high-
risk patients. Therefore, it is essential to perform the correct 
preoperative evaluation of patients in order to classify them 
as normal or high-risk cataract patients.
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